Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.

Deborah E. Citrin, Pataje G.S. Prasanna, Amanda Walker, Michael L. Freeman, Iris Eke, Mary Helen Barcellos-Hoff, Molykutty J. Arankalayil, Eric P. Cohen, Ruth C. Wilkins, Mansoor M. Ahmed, Mitchell S. Anscher, Benjamin Movsas, Jeffrey C. Buchsbaum, Marc S. Mendonca, Thomas A. Wynn, C. Norman Coleman

Research output: Contribution to journalReview article

Abstract

A workshop entitled "Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate" (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF, (c) discuss opportunities for pharmacological mitigation, intervention and modulation of specific molecular pathways, (d) consider the design of optimal clinical trials for mitigation and treatment and (e) outline key regulatory nonprescriptive frameworks for approval.

Original languageEnglish (US)
Pages (from-to)1-20
Number of pages20
JournalRadiation research
Volume188
Issue number1
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Radiation Pneumonitis
fibrosis
National Cancer Institute (U.S.)
cancer
Education
radiation
Radiation Oncology
Clinical Trials
Research
Radiobiology
Translational Medical Research
Therapeutic Uses
Biomarkers
biomarkers
Pharmacology
Radiation
biology
Wounds and Injuries
therapy

ASJC Scopus subject areas

  • Biophysics
  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

Citrin, D. E., Prasanna, P. G. S., Walker, A., Freeman, M. L., Eke, I., Barcellos-Hoff, M. H., ... Coleman, C. N. (2017). Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016. Radiation research, 188(1), 1-20. https://doi.org/10.1667/RR14784.1

Radiation-Induced Fibrosis : Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016. / Citrin, Deborah E.; Prasanna, Pataje G.S.; Walker, Amanda; Freeman, Michael L.; Eke, Iris; Barcellos-Hoff, Mary Helen; Arankalayil, Molykutty J.; Cohen, Eric P.; Wilkins, Ruth C.; Ahmed, Mansoor M.; Anscher, Mitchell S.; Movsas, Benjamin; Buchsbaum, Jeffrey C.; Mendonca, Marc S.; Wynn, Thomas A.; Coleman, C. Norman.

In: Radiation research, Vol. 188, No. 1, 01.07.2017, p. 1-20.

Research output: Contribution to journalReview article

Citrin, DE, Prasanna, PGS, Walker, A, Freeman, ML, Eke, I, Barcellos-Hoff, MH, Arankalayil, MJ, Cohen, EP, Wilkins, RC, Ahmed, MM, Anscher, MS, Movsas, B, Buchsbaum, JC, Mendonca, MS, Wynn, TA & Coleman, CN 2017, 'Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.', Radiation research, vol. 188, no. 1, pp. 1-20. https://doi.org/10.1667/RR14784.1
Citrin, Deborah E. ; Prasanna, Pataje G.S. ; Walker, Amanda ; Freeman, Michael L. ; Eke, Iris ; Barcellos-Hoff, Mary Helen ; Arankalayil, Molykutty J. ; Cohen, Eric P. ; Wilkins, Ruth C. ; Ahmed, Mansoor M. ; Anscher, Mitchell S. ; Movsas, Benjamin ; Buchsbaum, Jeffrey C. ; Mendonca, Marc S. ; Wynn, Thomas A. ; Coleman, C. Norman. / Radiation-Induced Fibrosis : Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016. In: Radiation research. 2017 ; Vol. 188, No. 1. pp. 1-20.
@article{9188bf4ac75e4a8aa199651b065355e8,
title = "Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.",
abstract = "A workshop entitled {"}Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate{"} (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF, (c) discuss opportunities for pharmacological mitigation, intervention and modulation of specific molecular pathways, (d) consider the design of optimal clinical trials for mitigation and treatment and (e) outline key regulatory nonprescriptive frameworks for approval.",
author = "Citrin, {Deborah E.} and Prasanna, {Pataje G.S.} and Amanda Walker and Freeman, {Michael L.} and Iris Eke and Barcellos-Hoff, {Mary Helen} and Arankalayil, {Molykutty J.} and Cohen, {Eric P.} and Wilkins, {Ruth C.} and Ahmed, {Mansoor M.} and Anscher, {Mitchell S.} and Benjamin Movsas and Buchsbaum, {Jeffrey C.} and Mendonca, {Marc S.} and Wynn, {Thomas A.} and Coleman, {C. Norman}",
year = "2017",
month = "7",
day = "1",
doi = "10.1667/RR14784.1",
language = "English (US)",
volume = "188",
pages = "1--20",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "Radiation Research Society",
number = "1",

}

TY - JOUR

T1 - Radiation-Induced Fibrosis

T2 - Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.

AU - Citrin, Deborah E.

AU - Prasanna, Pataje G.S.

AU - Walker, Amanda

AU - Freeman, Michael L.

AU - Eke, Iris

AU - Barcellos-Hoff, Mary Helen

AU - Arankalayil, Molykutty J.

AU - Cohen, Eric P.

AU - Wilkins, Ruth C.

AU - Ahmed, Mansoor M.

AU - Anscher, Mitchell S.

AU - Movsas, Benjamin

AU - Buchsbaum, Jeffrey C.

AU - Mendonca, Marc S.

AU - Wynn, Thomas A.

AU - Coleman, C. Norman

PY - 2017/7/1

Y1 - 2017/7/1

N2 - A workshop entitled "Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate" (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF, (c) discuss opportunities for pharmacological mitigation, intervention and modulation of specific molecular pathways, (d) consider the design of optimal clinical trials for mitigation and treatment and (e) outline key regulatory nonprescriptive frameworks for approval.

AB - A workshop entitled "Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate" (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF, (c) discuss opportunities for pharmacological mitigation, intervention and modulation of specific molecular pathways, (d) consider the design of optimal clinical trials for mitigation and treatment and (e) outline key regulatory nonprescriptive frameworks for approval.

UR - http://www.scopus.com/inward/record.url?scp=85021883280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021883280&partnerID=8YFLogxK

U2 - 10.1667/RR14784.1

DO - 10.1667/RR14784.1

M3 - Review article

C2 - 28489488

AN - SCOPUS:85021883280

VL - 188

SP - 1

EP - 20

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 1

ER -